Innoviva PE Ratio 2012-2026 | INVA
Current and historical p/e ratio for Innoviva (INVA) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Innoviva PE ratio as of June 05, 2026 is 5.88.
| Innoviva PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-08 | 22.33 | 3.72 | |
| 2026-03-31 | 23.30 | $6.01 | 3.88 |
| 2025-12-31 | 19.99 | $3.05 | 6.55 |
| 2025-09-30 | 18.25 | $1.54 | 11.85 |
| 2025-06-30 | 20.09 | $0.48 | 41.85 |
| 2025-03-31 | 18.13 | $-0.84 | 0.00 |
| 2024-12-31 | 17.35 | $0.36 | 48.19 |
| 2024-09-30 | 19.31 | $0.71 | 27.20 |
| 2024-06-30 | 16.40 | $1.67 | 9.82 |
| 2024-03-31 | 15.24 | $2.24 | 6.80 |
| 2023-12-31 | 16.04 | $2.20 | 7.29 |
| 2023-09-30 | 12.99 | $0.78 | 16.65 |
| 2023-06-30 | 12.73 | $2.60 | 4.90 |
| 2023-03-31 | 11.25 | $2.59 | 4.34 |
| 2022-12-31 | 13.25 | $2.37 | 5.59 |
| 2022-09-30 | 11.61 | $3.24 | 3.58 |
| 2022-06-30 | 14.76 | $1.34 | 11.01 |
| 2022-03-31 | 19.35 | $2.23 | 8.68 |
| 2021-12-31 | 17.25 | $2.87 | 6.01 |
| 2021-09-30 | 16.71 | $3.12 | 5.36 |
| 2021-06-30 | 13.41 | $2.48 | 5.41 |
| 2021-03-31 | 11.95 | $2.27 | 5.26 |
| 2020-12-31 | 12.39 | $2.02 | 6.13 |
| 2020-09-30 | 10.45 | $1.96 | 5.33 |
| 2020-06-30 | 13.98 | $2.06 | 6.79 |
| 2020-03-31 | 11.76 | $1.71 | 6.88 |
| 2019-12-31 | 14.16 | $1.43 | 9.90 |
| 2019-09-30 | 10.54 | $3.35 | 3.15 |
| 2019-06-30 | 14.56 | $3.42 | 4.26 |
| 2019-03-31 | 14.03 | $3.57 | 3.93 |
| 2018-12-31 | 17.45 | $3.53 | 4.94 |
| 2018-09-30 | 15.24 | $1.70 | 8.96 |
| 2018-06-30 | 13.80 | $1.48 | 9.32 |
| 2018-03-31 | 16.67 | $1.29 | 12.92 |
| 2017-12-31 | 14.19 | $1.17 | 12.13 |
| 2017-09-30 | 14.12 | $0.89 | 15.87 |
| 2017-06-30 | 12.80 | $0.81 | 15.80 |
| 2017-03-31 | 13.83 | $0.64 | 21.61 |
| 2016-12-31 | 10.70 | $0.53 | 20.19 |
| 2016-09-30 | 10.99 | $0.34 | 32.32 |
| 2016-06-30 | 10.53 | $0.17 | 61.94 |
| 2016-03-31 | 12.59 | $-0.03 | 0.00 |
| 2015-12-31 | 10.54 | $-0.16 | 0.00 |
| 2015-09-30 | 7.18 | $-0.32 | 0.00 |
| 2015-06-30 | 17.74 | $-0.47 | 0.00 |
| 2015-03-31 | 15.21 | $-0.97 | 0.00 |
| 2014-12-31 | 13.52 | $-1.50 | 0.00 |
| 2014-09-30 | 16.04 | $-1.85 | 0.00 |
| 2014-06-30 | 27.65 | $-2.10 | 0.00 |
| 2014-03-31 | 23.15 | $-1.90 | 0.00 |
| 2013-12-31 | 26.67 | $-1.67 | 0.00 |
| 2013-09-30 | 30.57 | $-1.53 | 0.00 |
| 2013-06-30 | 28.82 | $-1.46 | 0.00 |
| 2013-03-31 | 17.67 | $-1.51 | 0.00 |
| 2012-12-31 | 16.64 | $-0.19 | 0.00 |
| 2012-09-30 | 19.38 | $-0.31 | 0.00 |
| 2012-06-30 | 16.62 | $-0.31 | 0.00 |
| 2012-03-31 | 14.59 | $-0.20 | 0.00 |
| 2011-12-31 | 16.53 | $-1.41 | 0.00 |
| 2011-09-30 | 15.07 | $-1.20 | 0.00 |
| 2011-06-30 | 16.61 | $-1.12 | 0.00 |
| 2011-03-31 | 18.12 | $-1.09 | 0.00 |
| 2010-12-31 | 18.75 | $-1.16 | 0.00 |
| 2010-09-30 | 15.04 | $-1.26 | 0.00 |
| 2010-06-30 | 9.40 | $-1.32 | 0.00 |
| 2010-03-31 | 9.96 | $-1.39 | 0.00 |
| 2009-12-31 | 9.78 | $-1.35 | 0.00 |
| 2009-09-30 | 10.95 | $-1.27 | 0.00 |
| 2009-06-30 | 10.95 | $-1.26 | 0.00 |
| 2009-03-31 | 12.72 | $-1.35 | 0.00 |
| 2008-12-31 | 9.27 | $-1.53 | 0.00 |
| 2008-09-30 | 9.32 | $-1.81 | 0.00 |
| 2008-06-30 | 8.88 | $-2.00 | 0.00 |
| 2008-03-31 | 7.88 | $-2.31 | 0.00 |
| 2007-12-31 | 14.59 | $-2.64 | 0.00 |
| 2007-09-30 | 19.52 | $-2.72 | 0.00 |
| 2007-06-30 | 23.94 | $-2.82 | 0.00 |
| 2007-03-31 | 22.07 | $-2.77 | 0.00 |
| 2006-12-31 | 23.11 | $-2.81 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |